Introduction {#Sec1}
============

Prostate cancer is currently the most frequent solid neoplasm and the third cause of death in European men \[[@CR1]\]. The increased tumor detection is associated with the use of the prostate-specific antigen testing, which changed the epidemiology of this tumor, by moving diagnosis to younger patients at earlier stages. Now, men have to live longer with their disease and with the treatment's side effects, which are mainly urinary, sexual and bowel problems \[[@CR2], [@CR3]\]. Therefore, Patient-Reported Outcomes (PROs), such as health-related quality of life (HRQL), have achieved an important role in the evaluation of treatment benefits and harms in these patients \[[@CR4], [@CR5]\]. The first prostate cancer-specific HRQL instruments, such as the prostate module of the European Organization for Research and Treatment of Cancer (EORTC QLM-P14) \[[@CR6]\] or the Prostate Cancer-Specific Quality of Life Instrument (PROSQOLI) \[[@CR7]\], were designed mainly for patients in advanced disease stages and present significant limitations when used in patients with localized disease.

The need for tools capable of capturing all relevant aspects in patients diagnosed at early stages of disease led to the development of several prostate cancer-specific instruments. A recent systematic review \[[@CR8]\] identified almost 30 symptom measures either designed or adapted for prostate cancer patients. Several share a similar content and applicability, which makes it a complicated task to select the right instrument for a specific purpose and setting, calling for the need to evaluate those measures considering their strengths and weaknesses. The right choice depends on both the instrument's characteristics and the specific study requirements (mainly objectives and available resources). A comparative evaluation among instruments would be of great value to facilitate this selection task.

Several attempts have been made to systemize evaluation criteria for PROs. The GraQol Index was the first instrument that generated a global score \[[@CR9]\]. Currently, there are two other tools used for this purpose, the COnsensus-based Standards for the selection of health status Measurement INstruments (COSMIN) \[[@CR10]\], and the Evaluating Measures of Patient-Reported Outcomes (EMPRO) \[[@CR11]\]. While the COSMIN was developed as a checklist for evaluating the methodological quality of each individual study, the EMPRO was designed to assess the quality of the PRO measure by taking into account all the available studies. EMPRO considers both the methods applied in the studies and the adequacy of the results.

The quality of a PRO measure was defined by the EMPRO developers as the "degree of confidence that all possible bias has been minimized and that the information about the process which led to its development and evaluation is clear and accessible" \[[@CR11]\]. The EMPRO combines 3 fundamental aspects: (1) well-described and established attributes for assessment, (2) expert reviewers to conduct the assessment, and (3) scores that allow a direct comparison among outcome measures. It is based on an exhaustive series of recommendations regarding the ideal attributes of PRO measures \[[@CR12]\]. The EMPRO is a valid and reliable tool that has proven its usefulness in comparing the performance of generic \[[@CR11]\] and disease-specific PROs, such as heart failure \[[@CR13]\] and shoulder disorders \[[@CR14]\].

Reviews have been published which identify \[[@CR15]\], classify \[[@CR16]--[@CR20]\] or evaluate \[[@CR8], [@CR21], [@CR22]\] PRO measures for prostate cancer patients. However, none of these reviews used a validated tool for the evaluation. The focus of the latter three evaluative reviews differed a lot: from generic, cancer- and prostate cancer-specific PRO instruments \[[@CR21], [@CR22]\] to symptom measures \[[@CR8]\]. The number of instruments evaluated varied accordingly from 16 \[[@CR22]\] to 29 \[[@CR8]\]. Our study focus was set on instruments measuring the impact of localized prostate cancer and treatment side effects on patients' HRQL, and not just measuring the frequency of symptoms. The aim of our study was to obtain a systematic and standardized EMPRO evaluation of the evidence available on development process, metric properties and administration issues of prostate cancer-specific HRQL instruments that are currently applicable in patients with early-stage disease.

Methods {#Sec2}
=======

Systematic review {#Sec3}
-----------------

We identified the prostate cancer-specific HRQL instruments by reviewing the Patient-Reported Outcomes and Quality of Life Instruments Database (PROQOLID) \[[@CR23]\] and the websites of two cancer research groups: European Organization for Research and Treatment of Cancer (EORTC)[1](#Fn1){ref-type="fn"} and Functional Assessment of Cancer Therapy Group (FACT).[2](#Fn2){ref-type="fn"} We also examined topic-related review articles \[[@CR8], [@CR15]--[@CR22]\] and their bibliographic reference lists. We included prostate cancer-specific HRQL instruments that were applicable to patients with localized disease. We excluded instruments that are domain- or treatment-specific, such as the Sexual Health Inventory for Men instrument \[[@CR24]\], or the Prostatectomy Therapy Survey Instrument \[[@CR25]\].

Once the instruments were identified (five through PROQOLID, EORTC and FACT; and three through review articles in PubMed), we carried out systematic searches for each instrument in the PubMed database (September 2013) in order to obtain all the available published evidence. The search strategy combined the keywords "urologic cancer" or "prostate cancer" and "quality of life" and the name of the instrument (full name and abbreviation), both as MeSH terms and free-text entries (see Online Appendix 1). Articles were eligible for inclusion if they contained information regarding the development process of the instrument, its metric properties and administration issues. We only considered original research articles published in English, Spanish, French or German.

In a two-step process, abstracts and full-text articles were independently reviewed by two investigators (S.S. and Virginia Becerra). A third investigator (M.F.) mediated and resolved discrepancies in each step. We then manually examined the bibliographic reference lists of the articles selected for full review.

Evaluating Measures of Patient-Reported Outcomes (EMPRO) {#Sec4}
--------------------------------------------------------

The EMPRO \[[@CR11]\] was designed to measure the quality of PRO instruments. It assesses quality as an overall concept, which is based on eight attributes (39 items) covering: "conceptual and measurement model" (concepts and population intended to assess); "reliability" (to which degree an instrument is free of random error); "validity" (to which degree an instrument measures what it intends); "responsiveness" (ability to detect change over time); "interpretability" (assignment of meanings to instruments' scores); "burden" (time, effort and other demands for administration and response); "alternative modes of administration" (i.e., self- or interviewer-administered, telephone or computer-assisted interview); and "cross-cultural and linguistic adaptations" (equivalence across translated versions). For instruments which had some country versions available (e.g., Canadian, Dutch, Italian, Japanese and Spanish \[[@CR26]--[@CR30]\] University of California Los Angeles-Prostate Cancer Index (UCLA-PCI) versions), their studies were considered in the EMPRO evaluation. Nevertheless, the "cross-cultural and linguistic adaptation" attribute was not completed because the separate evaluation of every version was beyond the scope of this study.

All EMPRO attributes and items are accompanied by a short description to facilitate understanding the intended meaning and to guarantee a standardized application during the evaluation process. The item content for each attribute is summarized in the table of EMPRO results. Agreement with each item can be answered on a four-point Likert's scale, from 4 (strongly agree) to 1 (strongly disagree). The "no information" box can be checked in case of insufficient information. Five items allow replying with "not applicable." It is recommended to provide detailed comments to justify each EMPRO rating. These comments aid in the interpretation of the EMPRO scores.

Standardized EMPRO evaluation {#Sec5}
-----------------------------

Each prostate cancer-specific instrument was evaluated by two different experts using the EMPRO tool. Experts were identified and invited because of their expertise and experience in PRO measurement: Eight were senior researchers who belonged to the EMPRO tool development working group, and the other eight were junior researchers who had previously been certified as EMPRO experts after participating in a training course and successfully completing a supervised evaluation. The review pairs were composed of one senior and one junior researcher. In order to minimize the potential bias, experts were not authors nor had been involved in the development or adaptation process of their assigned instrument.

The EMPRO evaluation process consisted of two consecutive rounds. In the first round, every expert independently evaluated his or her assigned instrument by reviewing the full-text articles identified through the systematic review process and by applying the EMPRO tool \[[@CR11]\]. In the second round, each expert was provided with the rating results of the other expert who had this instrument assigned. In case of discrepancies, first, they were invited to resolve them through consensus, and second, if necessary, they were solved by a third reviewer.

Statistical analysis {#Sec6}
--------------------

Attribute-specific scores and an overall score were calculated. Detailed information and algorithms to obtain EMPRO scores are available online.[3](#Fn3){ref-type="fn"} First, the mean of the applicable items was calculated for each attribute (when at least 50 % of them were rated); and second, this raw mean was linearly transformed into a range of 0 (worst possible score)--100 (best possible score). Items for which the response option "no information" had been selected were assigned a score of 1 (lowest possible score). Separate subscores for the "reliability" and "burden" attributes were calculated as they are composed of two components each: "internal consistency" and "reproducibility" for reliability, as well as "respondent" and "administrative" for burden. For reliability, the highest subscore for the two components was then chosen to represent the attribute.

Besides the attribute-specific scores, an overall score was computed by calculating the mean of the five metric-related attributes: "conceptual and measurement model," "reliability," "validity," "responsiveness to change" and "interpretability." The overall score was only calculated when at least three of these five attributes had a score. EMPRO scores were considered reasonably acceptable if they reached at least 50 points (out of the 100 maximum theoretical points). This threshold was chosen based on the global recommendations made by the reviewers in the first two EMPRO studies \[[@CR11], [@CR13]\]. The receiver operating characteristic (ROC) curve was calculated to evaluate the agreement between EMPRO attribute scores and the reviewers' global recommendations. The area under the ROC curve was of 0.87 and the suggested cutoff was 51 (data not shown but available upon request).

Results {#Sec7}
=======

Characteristics of instruments {#Sec8}
------------------------------

We identified eight HRQL instruments applicable to patients with early-stage prostate cancer, which were developed between 1997 and 2008 (Table [1](#Tab1){ref-type="table"}). Four instruments were designed for all tumor stages (Estudio sobre la Calidad de Vida en el Cáncer de Próstata---ESCAP-CDV \[[@CR31]\], EORTC QLQ-PR25 \[[@CR32]\], FACT-P \[[@CR33]\], and Patient-Oriented Prostate Utility Scale---PORPUS \[[@CR34]\]) and the other four were developed specifically for patients at early-stage disease (Expanded Prostate Cancer Index Composite---EPIC \[[@CR35]\], Prostate Cancer Quality of Life Instrument---PC-QoL \[[@CR36]\], Prostate Cancer Symptom Indices---PCSI \[[@CR37]\] and UCLA-PCI \[[@CR38]\]). The EORTC QLQ-PR25 \[[@CR32]\] and FACT-P \[[@CR33]\] are tumor location-specific modules and were developed to complement the corresponding cancer-specific core questionnaire that measures general well-being (EORTC QLQ-C30 and FACT-General, respectively). The ESCAP-CDV \[[@CR31]\] is a Spanish instrument which covers eight dimensions of general health and one prostate cancer-specific module. The PORPUS \[[@CR34]\] is a unidimensional utility instrument composed by five general health and five prostate cancer-specific questions. Most of the instruments differentiate among bowel, sexual and urinary domains. EPIC \[[@CR35]\] was developed from the UCLA-PCI \[[@CR38]\] by supplementing it with items focusing on urinary irritative and obstructive voiding symptoms, as well as a hormonal domain. EORTC-PR25 and EPIC are the only instruments that consider the whole symptom spectrum (urinary, bowel, sexual and hormonal) in their content.Table 1Summarized characteristics of the evaluated prostate cancer-specific quality of life instrumentsInstrumentAuthorNo. of manuscripts^a^Purpose of developmentDisease stageResponse option; score rangeTime frameworkNo. of items (time to complete)No. of domainsDomains measured (no. of items)BowelSexualUrinaryOther1. ESCAP-CDVMorales et al. \[[@CR31]\]2To design a prostate cancer-specific QoL instrument valid in Spanish population, based on the EORTC QLQ-C3All stagesFour-point Likert's (lower scores mean better QoL)Last 4 weeks34 (10′)9------Eight general health domains (30)\
One prostate cancer-specific domain (6)2. EORTC QLQ-PR25Van Andel et al. \[[@CR32]\]5 (3)To assess treatment-related complications of prostate cancer therapyAll stagesFour-point Likert's; 0--100^b^Last 1--4 weeks25 (15′)6B. symptom (4)S. active (2)\
S. functioning (1^c^)U. symptom (8)\
Incontinence aid (1^c^)Hormonal symptom (6)3. EPICWei et al. \[[@CR35]\]13 (4)To facilitate a more comprehensive QoL assessment by capturing impact of new treatmentsEarly stageFive-point Likert's; 0--100 (worst to best)Last 4 weeks50 (20′ with SF-12)4 (8 subscales)B. summary (14)\
B. function (7)\
B. bother (7)S. summary (13)\
S. function (9)\
S. bother (4)U. summary (12)\
U. incontinence (4)\
U. irritative-obstructive (7)Hormonal summary (11)\
Hormonal function (5)\
Hormonal bother (6)4. FACT-PEsper et al. \[[@CR33]\]12 (3)To assess treatment-related complications of prostate cancer therapyAll stagesFive-point Likert's; 0--48 (worst to best)Last week12 (8--10′)1--------5. PC-QoLGiesler et al. \[[@CR36]\]3To develop a comprehensive instrument for use in clinic and research settingsEarly stage4--6-point Likert's; 0--100 (worst to best)Last 4 weeks52 (15′)10B. function (7)\
B. role activity limitation (5)\
B. bother (4)S. function (7)\
S. role activity limitation (5)\
S. bother (6)U. function (5)\
U. role activity limitation (5)\
U. bother (4)Cancer worry (4)6. PCSIClark et al. \[[@CR37]\]5To assess treatment-related complications of early prostate cancer therapyEarly Stage4--5-point Likert's; 0--100 (best to worst)Last 1--4 weeks29 (n.i.)8B. dysfunction (6)\
B. symptom distress (4)S. dysfunction (5)\
S. symptom distress (2)Incontinence dysfunction (3)\
O--I dysfunction (5)\
Incontinence distress (1)\
O--I distress (5)--7. PORPUSKrahn et al. \[[@CR34]\]5To develop a health-state classification system for multiple purposes (econometric and psychometric methods)All stages4--6-point Likert's; 0--1 (death to best health)Last 2 weeks10 (n.i.)1--------8. UCLA-PCILitwin et al. \[[@CR38]\]16 (5)To assess health concerns central to patients that undergo surgery or radiotherapyEarly stage3--5-point Likert's; 0--100 (worst to best)Last 4 weeks20 (20′ with SF-36)6B. function (4)\
B. bother (1)S. function (8)\
S. bother (1)U. function (5)\
U. bother (1)--Instruments: *ESCAP*-*CDV* Estudio sobre la Calidad de Vida en el Cáncer de Próstata, *EORTC QLQ*-*PR25* European Organization for Research and Treatment in Cancer, Quality of Life Group-Prostate Cancer Module, *EPIC* Expanded Prostate Cancer Index Composite, *FACT*-*P* Functional Assessment of Cancer Therapy-Prostate Cancer Module, *PC*-*QoL* Prostate Cancer Quality of Life Instrument, *PCSI* Prostate Cancer Symptom Indices, *PORPUS* Patient-Oriented Prostate Utility Scale, *UCLA*-*PCI* University of California Los Angeles-Prostate Cancer Index*O*--*I* obstruction/irritation, *n.i.* no information, *QoL* quality of life^a^Number of manuscripts used in the EMPRO evaluation. In brackets, the number of manuscripts reporting studies performed with country-specific versions^b^Higher scores reflecting either more symptoms (urinary, bowel, hormonal) or higher levels of functioning (sexual)^c^Conditional item

Retrieved information {#Sec9}
---------------------

The number of articles initially retrieved from the systematic literature search varied a lot, ranging from 323 (UCLA-PCI) to only two (ESCAP-CDV). The results of the systematic review process are described in Table [2](#Tab2){ref-type="table"}. Most of the articles were excluded because they were not related to the instrument or did not provide any information on development process, metric properties or administration issues. The final number of articles included in the EMPRO evaluation varied from 16 (UCLA-PCI) to two (ESCAP-CDV) (Table [1](#Tab1){ref-type="table"}). The bibliographic references of the included studies are shown in the Online Appendix 2.Table 2Results of the systematic literature review. Number of manuscripts identified, excluded and used in the EMPRO evaluationInstrument: abbreviation and full nameTotal manuscripts identifiedManuscripts excludedManuscripts with metric information (country-specific)Without instrument informationWithout metric informationOther languageTotal excludedESCAP-CDV2------02EORTC QLQ-PR2523618151--2325 (3)EPIC23670151222313 (4)FACT-P18210959217012 (3)PC-QoL14513210--1423PCSI27157--225PORPUS1226--85UCLA-PCI32391216130716 (5)Instruments: *ESCAP-CDV* Estudio sobre la Calidad de Vida en el Cáncer de Próstata, *EORTC QLQ-PR25* European Organization for Research and Treatment in Cancer, Quality of Life Group-Prostate Cancer Module, *EPIC* Expanded Prostate Cancer Index Composite, *FACT-P* Functional Assessment of Cancer Therapy-Prostate Cancer Module, *PC-QoL* Prostate Cancer Quality of Life Instrument, *PCSI* Prostate Cancer Symptom Indices, *PORPUS* Patient-Oriented Prostate Utility Scale, *UCLA-PCI* University of California Los Angeles-Prostate Cancer Index

Results of the EMPRO ratings {#Sec10}
----------------------------

Detailed EMPRO results of the standardized evaluation are presented in Table [3](#Tab3){ref-type="table"} and summarized in figure [1](#Fig1){ref-type="fig"}. Consensus between the two experts of an instrument was achieved in almost all cases, and the third expert was only needed to solve discrepancies for one instrument. The overall score, which summarizes the five attribute-specific scores described above, ranged from 83.1 (EPIC) to 21.1 (ESCAP-CDV). In the "conceptual and measurement model" attribute, instruments scored from 90.5 (EPIC, UCLA-PCI) to 42.9 (ESCAP-CDV, FACT-P), with six out of eight instruments presenting scores higher than 50. "Reliability" scores ranged from 75 (PC-QoL) to 25 (FACT-P), and only three instruments scored above the threshold of 50. "Validity" scores ranged from 100 (PORPUS) to 25.0, with only one instrument below 50 (ESCAP-CDV). In "responsiveness," instruments scored from 100 (PC-QoL) to 33.3 (EORTC-PR25), and six out of eight instruments scored higher than 50. "Interpretability" scores were highest for FACT-P (88.9), followed by EPIC, PORPUS and UCLA-PCI (each 77.8), though no information was found for three instruments. UCLA-PCI and PC-QOL presented the lowest respondent burden (66.7 and 55.6 points, respectively) and, together with EPIC, also the lowest administrative burden (ranging from 91.7 to 75 points).Table 3Ratings of each EMPRO item and attribute for every prostate cancer-specific quality of life instrument identifiedAttributesESCAP-CDVEORTC PR25EPICFACT-PPC-QoLPCSIPORPUSUCLA-PCIConcept and measurement model42.952.490.542.957.166.752.490.5 1. Concept of measurement stated++++++++++++++++++++++++++++++++ 2. Obtaining and combining items described+++++++++++++++++++++++++ 3. Rationality for dimensionality and scales++++++++++++++++++++++ 4. Involvement of target population+++++++++++++++++++++++++++ 5. Scale variability described and adequate++++++++++++++++++++++ 6. Level of measurement described+++++++--+++++ 7. Procedures for deriving scores+++++++++++++++++++Reliability---total score37.562.566.725.07537.533.337.5 Reliability: internal consistency37.562.562.525.07537.537.5  8. Data collection methods described++++++++++++++++++++--++  9. Cronbach's alpha adequate++++++++++++++++--+++  10. IRT estimates provided----------------  11. Testing in different populationsn.a.n.a.n.a.n.a.n.a.n.a.n.a.n.a. Reliability: reproducibility33.366.705016.733.333.3  12. Data collection methods described++--++++++++++++++++  13. Test--retest and time interval adequate++--++++++++++++++  14. Reproducibility coefficients adequate+++--+++++++--++++  15. IRT estimates provided--+++------------Validity25.05091.758.391.75010091.7 16. Content validity adequate++++++++++++++++++++++ 17. Construct/criterion validity adequate++++++++++++++++++++++++++ 18. Sample composition described+++++++++++++++++++++++++ 19. Prior hypothesis stated++++++++++++++++++++++++++ 20. Rational for criterion validityn.a.n.a.n.a.n.a.n.a.n.a.n.a.n.a. 21. Tested in different populationsn.a.n.a.n.a.n.a.n.a.n.a.n.a.n.a.Responsiveness33.388.955.610055.688.988.9 22. Adequacy of methods--+++++++++++++++++++++++ 23. Description of estimated magnitude of change--++++++++++++++++++++++++ 24. Comparison of stable and unstable groups----+++++++++++++++++++Interpretability77.888.955.677.877.8 25. Rational of external criteria----++++++--++++++++++ 26. Description of interpretation strategies----+++++++--++++++++ 27. How data should be reported stated----++++++++--++++++++++**OVERALL SCORE21.139.783.154.164.853.170.577.3**Burden Burden: respondent22.233.344.422.255.6066.7  28. Skills and time needed++++++++++++--+++++  29. Impact on respondents++++++++++++++--+++++  30. Not suitable circumstances---------------- Burden: administrative91.7758.391.7  31. Resources required----++++--++++--+++++  32. Time required----++++--++++--++++++  33. Training and expertise needed----+++--++++----++++  34. Burden of score calculation++++++++------+++Explanation: ++++ 4 (strongly agree), +++ 3, ++ 2, + 1 (strongly disagree), -- no information, *n.a.* not applicable. The higher the agreement the better the ratingInstruments: *ESCAP*-*CDV* Estudio sobre la Calidad de Vida en el Cáncer de Próstata, *EORTC QLQ*-*PR25* European Organization for Research and Treatment in Cancer, Quality of Life Group-Prostate Cancer Module, *EPIC* Expanded Prostate Cancer Index Composite, *FACT*-*P* Functional Assessment of Cancer Therapy-Prostate Cancer Module, *PC*-*QoL* Prostate Cancer Quality of Life Instrument, *PCSI* Prostate Cancer Symptom Indices, *PORPUS* Patient-Oriented Prostate Utility Scale, *UCLA*-*PCI* University of California Los Angeles-Prostate Cancer IndexFig. 1Overall ranking of instruments and their attribute-specific EMPRO scores. EMPRO scores ranged 0--100 (worst to best). Instruments: *ESCAP*-*CDV* Estudio sobre la Calidad de Vida en el Cáncer de Próstata, *EORTC QLQ*-*PR25* European Organization for Research and Treatment in Cancer, Quality of Life Group-Prostate Cancer Module, *EPIC* Expanded Prostate Cancer Index Composite, *FACT*-*P* Functional Assessment of Cancer Therapy-Prostate Cancer Module, *PC*-*QoL* Prostate Cancer Quality of Life Instrument, *PCSI* Prostate Cancer Symptom Indices, *PORPUS* Patient-Oriented Prostate Utility Scale, *UCLA*-*PCI* University of California Los Angeles-Prostate Cancer Index

EPIC and UCLA-PCI provide alternative forms of administration, as well as short forms whose evaluation is shown in Table [4](#Tab4){ref-type="table"}. Apart from the traditional paper mode, there is a web administration form for UCLA-PCI \[[@CR39]\] and a telephone administration with interactive voice response for EPIC \[[@CR40]\]. In both cases, the EMPRO score reached 50 points because the alternative administration method was compared extensively with the original, but without assessing the whole range of metric properties. EPIC short forms were well rated (70 points), as good metric properties were demonstrated for both EPIC-26 and EPIC-Clinical Practice, as well as their comparability with scores of the original instrument. UCLA-PCI short form was rated low because only internal consistency reliability was estimated.Table 4Alternative forms of administrationAttributeAdministration formsShort formsEPIC---interactive voice responseUCLA-PCI-web-based modeEPIC-26EPIC-clinical practiceUCLA-PCI short formAlternative forms505066.766.716.7 35. Metric characteristics of alternative forms++--++++++++ 36. Comparability of alternative forms+++++++++++++--Explanation: ++++ 4 (strongly agree), +++ 3, ++ 2, + 1 (strongly disagree), -- no information. The higher the agreement the better the rating

Discussion {#Sec11}
==========

In this study, we assessed the performance of patient self-reported HRQL instruments applicable for early-stage prostate cancer disease. Information regarding development process, metric properties, and administrative issues was obtained in systematic reviews of the literature and was evaluated by experts using a standardized tool. Of the eight instruments, the best rate according to EMPRO standard criteria was found for EPIC. Results obtained by UCLA-PCI, PORPUS and PC-QoL also support good performance, and therefore, their use should be recommended. FACT-P and PCSI scored slightly above the threshold of acceptable results, while ESCAP-CDV is far from this minimum quality criterion.

EPIC and UCLA-PCI {#Sec12}
-----------------

The EPIC and UCLA-PCI scored the highest in the overall EMPRO assessment. In our study, both instruments were the best in "concept and measurement model," and obtained very high "validity," "responsiveness," and "interpretability" results, where they were placed at second position. Despite these good results of UCLA-PCI, we recommend EPIC (its upgrade) not only due to its good reliability, but also because it incorporates a hormonal domain and urinary subscales for incontinence and irritative--obstructive symptoms (while UCLA-PCI's urinary domain mainly queries incontinence). Both questionnaires have developed brief versions to minimize administration burden. The EPIC-26 \[[@CR41]\] shortened to 10 min the time required to complete, and the EPIC for Clinical Practice \[[@CR42]\] with 16 items was designed to be administered and scored directly during the clinical visit. The short UCLA-PCI \[[@CR43]\] contains 14 of the original 20 items.

PORPUS {#Sec13}
------

PORPUS obtained the third best rating in the overall summary score. It is the only prostate cancer-specific instrument combining econometric and psychometric methods. As a result, it can be used as a preference-based health index obtaining utilities (PORPUS-U) for economic evaluation or as a short descriptive HRQL profile (PORPUS-P) \[[@CR34]\]. In our metric quality evaluation, it was at the top for "validity" (maximum score), and it ranked second, equal to EPIC and UCLA-PCI, for "responsiveness" and "interpretability." However, it just passed the requirements of "conceptual and measurement model" as experts highlighted the need to clarify the different elicitation methods to obtain utilities with PORPUS-U: direct methods with standard gamble or rating scale (PORPUS-U~SG~ and PORPUS-U~RS~), and an indirect method with standard gamble (PORPUS-U~I~) \[[@CR44], [@CR45]\]. EMPRO scores for reliability were low because the intraclass correlation coefficient of PORPUS-U was 0.66 \[[@CR44]\] (lower than 0.7), and the test--retest design was insufficiently described. The PORPUS is the only prostate cancer-specific instrument for which general population-based norms exist to facilitate its score interpretation \[[@CR46]\].

PC-QoL and PCSI {#Sec14}
---------------

The PC-QoL obtained the fourth best rating in the overall summary score. Despite being at the top on "reliability" and "responsiveness" and the second on "validity," it is penalized for lacking information on "interpretability." The first version \[[@CR36]\] consisted of 52 items summarized in 10 domains. Befort et al. \[[@CR47]\] revised the instrument and made it a 46-item questionnaire with eight scales that also provides adequate metric properties. The PCSI ranked sixth on the overall score and met the minimum quality criteria for all the attributes except "reliability." The authors proposed the use of internal anchors employing the instrument's distress or bother items to establish cutoff points (good, intermediate or poor function) \[[@CR48]\]. This strategy was later deployed for the interpretation of other instruments such as EPIC and UCLA-PCI \[[@CR49], [@CR50]\]. It is the only instrument that considers patients' cancer worry.

FACT-P and EORTC QLQ-PR25 {#Sec15}
-------------------------

Overall performance of FACT-P was acceptable, while EORTC QLQ-PR25 did not reach the threshold of 50 points. FACT-P was at the top for "interpretability," with a 2--3 point clinically meaningful change estimation using anchor-based and distribution-based methods \[[@CR51]\], but it presented low scores on reliability mainly because of poor rates on study methods and internal consistency results (Cronbach's *α* below 0.7 \[[@CR33]\]). On the other hand, since the clinically meaningful change was estimated among patients suffering from metastatic hormone-refractory prostate cancer, its applicability for localized disease merits further research. EORTC QLQ-PR25 is strongly penalized due to the lack of information regarding its interpretability and for providing inadequate results on responsiveness. Experts highlighted that the coefficient used to estimate the magnitude of change was insufficiently described \[[@CR32]\], and no comparison with a stable group had been performed. However, it should be taken into account that EORTC QLQ-PR25 was the newest instrument, and to date, it has few publications in biomedical literature databases. EORTC and FACT developed their modules simultaneously in several languages, which represent an advantage to consider when choosing an instrument for multicentric international studies requiring different country versions.

Comparison with other evaluative reviews {#Sec16}
----------------------------------------

Our work has both similarities and differences when compared to the three evaluative reviews \[[@CR8], [@CR21], [@CR22]\]. Consistently with our findings, EPIC and UCLA-PCI are always among the most highly recommended \[[@CR8], [@CR21], [@CR22]\]; PC-QoL \[[@CR8], [@CR21]\] and PORPUS \[[@CR21]\] also obtained high ratings in other reviews; and the PCSI also met the minimum standard criteria to be recommended in the only other review where it was included \[[@CR8]\]. On the other hand, the only major difference detected with respect to previous reviews concerns the recommendation of FACT-P module. Rnic et al. \[[@CR8]\], similarly to our study, assigned it an unfavorable reliability evaluation according to the Cronbach's *α* coefficient of 0.65 and 0.69 reported by Esper et al. \[[@CR33]\]. Yet Hamoen et al. \[[@CR21]\] and the Oxford group \[[@CR22]\] recommended the FACT-P: the first article assigned full points to internal consistency \[[@CR21]\], and the second one rated it with "some limited evidence in favor" \[[@CR22]\]. These results suggest a higher exigency on the EMPRO requirements in comparison with other evaluations and differences on the evaluation criteria applied. Rnic et al. \[[@CR8]\] examined only 4 criteria (comprehensiveness, subjectivity of experience, internal consistency and extent of validation), while the attributes considered in the other two evaluations \[[@CR21], [@CR22]\] are similar to the EMPRO content. However, the only tool that generates attribute scores which are based on multiple items (ranging from 2 to 7) is EMPRO, thus resulting in a more exhaustive and comprehensive evaluation.

Study limitations {#Sec17}
-----------------

Our findings should be interpreted taking into account the study limitations. Firstly, the basis of our results is the information retrieved in systematic literature reviews conducted only in the PubMed database. Although it is the leading database in health sciences, we may have failed to identify all the published articles with information on development process, metric properties or administration issues. However, the sensitive search strategy specifically designed for each instrument, the additional hand search of references, as well as the double independent review process followed, may have minimized this problem. Secondly, the EMPRO evaluation is based on the quantity and quality of published evidence. A lack of evidence for a few EMPRO items or attributes penalizes the EMPRO scores, because the scoring algorithm counts any missing information as the worst possible rating. Nevertheless, to avoid a strong penalization, the EMPRO score is not calculated if more than half of the information is missing. Not presenting proposals for interpretability penalized the overall score for some of the instruments. Therefore, developing strategies to facilitate the interpretation of scores (such as estimating the minimal important difference by using anchor-based or distribution-based strategies, or providing reference values) is recommended. These interpretation proposals may help to extend these PRO measures beyond the research setting. Thirdly, EMPRO ratings may be biased by the individual expertise of the evaluators, although the double and independent review conducted, as well as a comprehensive description of each item, may have attenuated this concern. Fourthly, studies on metric properties from different country versions (EORTC PR25, EPIC, FACT-P and UCLA-PCI) were considered in our EMPRO evaluation. Although these country versions can add noise in one sense, they also provide valuable information about the generalizability of the psychometric data to these measures. Fifthly, although clinical trials can provide evidence on some metric properties such as validity, sensitivity to change or interpretability, none was included in our study. These trials were considered inappropriate because they were not specifically designed for the assessment of metric properties, nor included it as a secondary objective. For example, neither differences nor a lack of differences in PRO scores between trial arms could be interpreted as the instrument's responsiveness if there is no clear underlying hypothesis about change. Finally, as the standard error of measurement was not considered separately in EMPRO, the only information on the precision of the inferences at the individual level is based on the reliability of the instrument. Therefore, we cannot address the usefulness of these eight instruments at the individual patient's level.

Conclusions {#Sec18}
===========

In conclusion, the evidence would currently support a preference for the use of EPIC, PORPUS and PC-QoL. Choosing among them will mainly depend on particular study requirements. For longitudinal studies or clinical trials, where responsiveness and reproducibility are the maximum priority, PC-QoL or EPIC would be recommended. For economic evaluations, PORPUS would be chosen as it allows cost-utility analysis. The brief versions might be preferred to minimize administration burden: EPIC short \[[@CR41]\], EPIC-Clinical Practice \[[@CR42]\] or short UCLA-PCI \[[@CR43]\]. Our results facilitate the decision process regarding the correct instrument selection and its use and interpretation for a certain study purpose or setting.
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